Delivery Order 75D30124D20079-75D30124F00001
Award Date 9/6/24
Potential Completion Date 9/5/29
Potential Value $50M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for a delivery order under the "Test Surge and Data Sharing Multiple Award IDIQ" issued by the Centers for Disease Control and Prevention (CDC). The prime contractor is Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract has a ceiling value of $449,761.53 and a completion date of May 15, 2025. It is a time and materials contract type, with no set-aside designation. The contract leverages Ginkgo Bioworks' expertise...
- This federal contract award is for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Centers for Disease Control and Prevention (CDC) for "Test Surge and Data Sharing" services. The $118 million IDIQ was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts, on September 27, 2024. The contract has an ultimate completion date of September 5, 2029. This IDIQ is not designated as a set-aside contract. The IDIQ contract leverages...
- The Centers for Disease Control and Prevention (CDC) awarded a definitive firm fixed-price contract valued at $85.7 million to Ginkgo Bioworks, Inc., a Boston-based biotechnology company specializing in cellular engineering and genomic surveillance. The contract, awarded on February 28, 2025, supports the Traveler-Based Genomic Surveillance Program, with performance centered in Boston, MA and an ultimate completion date of March 21, 2028. This engagement represents a continuation of the...
- This is a $1,205,149.24 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract, titled "TRAVELER-BASED GENOMIC SURVEILLANCE," is for the provision of biotechnology services to support the CDC's public health monitoring and emergency response initiatives. The contract has an ultimate completion date of September 19, 2024 and was awarded on August 26, 2024....
- This firm-fixed-price contract was awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, for "Airport Genomic Testing". The contract, valued at $76,575,638.04, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers at five major U.S. airports, perform on-site reverse transcription polymerase chain reaction testing, whole genome sequencing, and collect and...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Ginkgo Bioworks, Inc. a $6.57 million firm fixed price definitive contract to support the Rapid Acceleration of Diagnostics-Advanced Technology Platforms program. The goal of this program is to increase SARS-CoV-2 testing capacity and throughput by identifying existing testing platforms that can be used for COVID-19 diagnostics. Work will be performed by Ginkgo Bioworks in Boston, Massachusetts over a one year...
- This is a $1,826,095.16 cost-plus-fixed-fee definitive contract awarded by the Naval Information Warfare Systems Command to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, for the "DNA Recording Intrinsic Cellular Biointelligence (DRINC BIO)" project. The contract, which does not have a set-aside designation, is for deobligation of excess funds and has an ultimate completion date of May 21, 2025. Ginkgo Bioworks is a for-profit manufacturer of goods and has a proven...
- Aegis Sciences Corporation, doing business as Aegis Analytical Laboratories, was awarded a delivery order valued at $2.43M under the CDC's Test Surge and Data Sharing Multiple Award IDIQ contract. The award, issued on September 27, 2024, with an ultimate completion date of September 26, 2029, is structured as a firm fixed-price delivery order with no set-aside designation. Work will be performed in Nashville, Tennessee, where Aegis maintains its primary laboratory operations. This delivery order...
- This is a delivery order awarded by the Centers for Disease Control and Prevention (CDC) to Aegis Sciences Corporation, a forensic toxicology and healthcare laboratory company, for a Test Surge and Data Sharing multiple-award indefinite-delivery, indefinite-quantity (IDIQ) contract. The delivery order, valued at $610,000.00, will task Aegis to provide science-driven drug testing and consulting services, including COVID-19 testing, genomic sequencing, and variant tracking out of its Nashville,...
- This is a $4,797,261 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston. The contract is for DARPA's "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS" program, which aims to develop technologies enabling immediate synthesis of bioactive protein medical countermeasures and production enzymes within 24 hours at a yield of at least 500 doses per week....